Abstract
The phosphoinositol-3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway is excessively activated in around 50% of breast cancer (BC). Metformin regulates negatively mTOR through AMPK-activation. The role of metformin in BC is unclear. We retrospectively analyzed the efficacy of metformin-chemotherapy association in a cohort of BC patients and explored mTOR-related proteins expression.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
